12:00 AM
 | 
Sep 06, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

MP4OX: Phase IIa data

In a double-blind, international Phase IIa trial in 51 severely injured trauma patients with lactic acidosis, 250 and 500 mL MP4OX each met the primary endpoint of significantly reducing serum lactate levels from baseline to 2 hours vs. 500 mL of Ringer's lactate solution (p=0.032 for each). Low- and high-dose MP4OX...

Read the full 235 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >